The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer

Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viab...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncogenesis
Autores principales: Xu, Meng-Dan, Liu, Lu, Wu, Meng-Yao, Jiang, Min, Shou, Liu-Mei, Wang, Wen-Jie, Wu, Jing, Zhang, Yan, Gong, Fei-Ran, Chen, Kai, Tao, Min, Zhi, Qiaoming, Li, Wei
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255842/
https://ncbi.nlm.nih.gov/pubmed/30478299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0102-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares